Additionally, a growing body of evidence has suggested an increasingly clearer link between MBI and AD biofluid and positron emission tomography (PET) biomarkers: greater amyloid‐β, phosphorylated tau, and neurofilament light pathological burden (Ghahremani et al., 2023; Ismail, Leon, et al., 2023; Johansson et al., 2021; Lussier et al., 2020; Miao et al., 2022; Naude et al., 2020; Naude et al., 2024). The gene discussed is MAPT; the disease is Alzheimer disease.